INO 5401 Vaccination in BRCA1/2 Mutation Carriers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
BRCA1/2 Mutation
Interventions
DRUG

INO-5401

INO-5401 contains genes which are active in human cancers (hTERT, PMSA, and WNT1) and are felt to be good targets for the immune system both people who have had cancer or for those at increased risk of getting cancer.

DRUG

INO-9012

INO-9012 contains the gene for IL12, a part of your body's immune system. It is possible that adding this to INO-5401 will increase the immune response to the vaccine.

DEVICE

Cellectra 2000

The device will deliver a small electric charge through 5 needles to increase the amount of the study vaccine taken up by the muscle.

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

University of Pennsylvania

OTHER

NCT04367675 - INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Biotech Hunter | Biotech Hunter